Method for treatment of disease by anti-TIGIT antibody in combination with PD-1 inhibitor and pharmaceutical combination

Abstract

The present disclosure relates to a method for treatment of disease by an anti-TIGIT antibody in combination with a PD-1 inhibitor and pharmaceutical combinations. Further, the present disclosure relates to the treatment of human TIGIT-related diseases (e.g., tumors) in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody) with a drug of an anti-TIGIT antibody or an antigen-binding fragment thereof.

Description

technical field [0001] The present disclosure relates to methods and drug combinations for treating diseases with anti-TIGIT antibodies combined with PD-1 inhibitors. Background technique [0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art. [0003] In recent years, immune checkpoint therapy targeting immune cell co-inhibitory receptors has made great progress in tumor immunotherapy, and the discovery and verification of new co-inhibitory receptors has become a global competitive hotspot. T cells are the key mediators of the immune response, and the activation of T cells depends on TCR signaling and co-stimulatory signals. Co-stimulatory signals are limiting signals for T cell activation, and their dysfunction is involved in the occurrence of autoimmune diseases (Immunol Rev, 2012, 248:122-139; AutoimmunRev, 2013, 12: 1171-1176). TIGIT (T cell immunoglobulin and ITIM domain) is a ...

AI Technical Summary

Problems solved by technology

However, Chew et al. found that the combination of TIGIT antibody and PD-1 antibody can promote the killing function of CD8 T cells against HIV and melanoma, but this effect disappears with the blockade of CD226 (Chew, Fujita et al.2016)

Images